The CANDY Project
In Europe, 10-15% of children and adults or 50 to 75 million individuals are affected by neurodevelopmental conditions, such as autism, attention-deficit hyperactivity disorder (ADHD), intellectual disability (ID), motor problems and language disorders. It is not hard to imagine that one of these conditions alone can have a serious impact on a person’s life. What makes the situation even worse is the fact that several of these conditions often co-exist and, on top of that, go along with somatic illnesses, such as epilepsy. This significantly affects both life expectancy and quality of life and there are no effective treatments to date.
In the CANDY project, we investigate the biological links between these neurodevelopmental conditions and co-existing somatic illnesses and how treatment and monitoring of affected patients can be improved.
of the EU population are affected by Neurodevelopmental Conditions such as autism, ADHD or ID
People on the autism spectrum experience persistent difficulties with social interaction and communication, display restricted and repetitive behaviour and/or have special circumscribed interests and activities. They often also experience sensory difficulties, such as increased or reduced sensitivity to light, sound, colour, smell, taste or touch.
ADHD belongs also to the group of neurodevelopmental conditions with onset usually occurring in childhood and adolescence. It manifests itself by problems with attention span and self-regulation and/or by impulsivity and high physical restlessness (hyperactivity). A clinical diagnosis is made when persistent symptoms are associated with impairments of functioning at home, school, workplace or during leasure time. However, symptoms alone are not sufficient for a diagnosis.
Intellectual disability (ID) is characterized by significant limitations both in intellectual functioning (reasoning, learning, problem solving) and in adaptive behavior, which covers a range of everyday social and practical skills. This disability originates before the age of 18.
“CANDY will improve our understanding of the overlap and associations between neurodevelopmental conditions and may have an impact on both the guidance for clinical assessment and for preventative and treatment strategies"
Prof. Jan Buitelaar, Coordinator
"I want to contribute to a better understanding of neurodevelopmental conditions. I believe this can aid in earlier intervention and finding more fitting support for people with a neurodevelopmental condition"
Ana Praat, Research Assistant
"Our team explores immune markers in the context of neurodevelopmental disorders (NDDs) to advance diagnostics and enhance understanding of their pathogenesis."
Dr. Ching-Lien WU, Scientist
"I am very excited about being part of a project that will help us understand the differences and similarities between different childhood onset diagnoses like ASD and ADHD, which is crucial for better individualized interventions in the future. "
Dr. Terje Falck-Ytter, Principle researcher
KIND at Karolinska Institutet
"Most people probably know at least one autistic person in their broader environment. I think that relating my research to what people see in their daily life can definitely make them understand why it is relevant."
Alexandra Abromeit, PhD candidate
"CANDY offers a framework to link animal and human data. By testing mice and preschoolers with a developmental delay in a comparable behavioural test battery, we not only advance the mechanistic understanding of the developmental changes in the preschoolers, but also enrich science with the availability of a validated translational test battery "
Prof. Judith Homberg
"I want to help, change and improve the identification, diagnosis and care of people with neurodevelopmental disorders. There's still so much to discover and do, it's fascinating!"
Marianne Mercier, Psychologist
"My research seeks to obtain detailed mechanistic insights and explores the multivariate mechanisms implicated in autism spectrum conditions to better understand the complexities of this condition."
Alejandro Rivera-Olvera, PhD candidate
"I’m involved in the cognitive tests, the imaging, and the contact with all of our parents. The best thing about testing are the children themselves. They always bring so much energy to the days, no day is the same!"
Sanne Kluin, Research Assistant
"Autistic people are much more likely to have epilepsy than the general population. We hope that this research will pave the way for new and more efficient treatments to address the symptoms of autistic people suffering from epilepsy and improve their quality of life."
Aurélie Baranger, Director
"I try to better understand the biological mechanisms that underlie Autism Spectrum Disorders.The ultimate goal of my research is to improve our understanding of sensory symptoms. Hopefully, this can contribute to the improvement of the quality of life for those who are affected by these symptoms."
Iris Riemersma, PhD
Project duration (months)
Read more about the “problem” and the opportunity in CANDY, and more detailed information about biomarkers, the microbiome, neuroinflammation and critical periods.
Facts & Figures »
The Team »
CANDY PIP Study
In CANDY we are collaborating with the AIMS-2-TRIALS project and their study “Pre-School Brain Imaging and Behaviour Project (PIP)”. PIP is the first study to track how pre-school children with and without autism develop over time and across Europe.
This is the first study to track the heritability of rare genetic risk variants for several neurodevelopmental conditions. Neurodevelopmental conditions likely result from a combination of both rare genetic variants and many common low-risk variants.
News & Events
Eva Loth becomes professor of Cognitive Neuroscience at King's Colleage London. On 16th June 2023, Eva Loth, gave her inaugural lecture as professor of Cognitive Neuroscience at the Institute of Psychiatry, Psychology and Neuroscience at King's Colleage London...
Recruitment completed at Karolinska InstitutetCongratulation to Sven Bölte and Terje Falck-Ytter and the whole team at Karolinska Institutet for completing the recruitment of 10 families for the Multiplex (MPX) study 👏👏👏 This is a big step forward for our the CANDY...
On 31st December 2022 the second CANDY project period has officially ended. This means the first 3 years have been completed and the CANYD consortium had to submit a detailed progress report to our funding organisation, the European Commission. Although we encounter a...